These results collectively support the potency of IL-34, M-CSF, CD68+-TAMs and the combination of IL-34 and CD68+-TAMs as novel biological markers for GC, thus may provide new insight for both diagnosis and cellular therapy of GC. This evidence concerns the gene CSF1 and gastric cancer.